Expert opinion on drug metabolism & toxicology最新文献_第5页

Development and application of a population pharmacokinetic model repository for caffeine dose tailoring in preterm infants. 为早产儿咖啡因剂量调整开发和应用群体药代动力学模型库。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-09-01 Epub Date: 2024-08-27 DOI: 10.1080/17425255.2024.2395561

Hao-Ran Dai, Hong-Li Guo, Ya-Hui Hu, Yun Liu, Ke-Yu Lu, Yuan-Yuan Zhang, Jie Wang, Xuan-Sheng Ding, Zheng Jiao, Rui Cheng, Feng Chen

{"title":"Development and application of a population pharmacokinetic model repository for caffeine dose tailoring in preterm infants.","authors":"Hao-Ran Dai, Hong-Li Guo, Ya-Hui Hu, Yun Liu, Ke-Yu Lu, Yuan-Yuan Zhang, Jie Wang, Xuan-Sheng Ding, Zheng Jiao, Rui Cheng, Feng Chen","doi":"10.1080/17425255.2024.2395561","DOIUrl":"10.1080/17425255.2024.2395561","url":null,"abstract":"Background: Considerable interindividual variability for the pharmacokinetics of caffeine in preterm infants has been demonstrated, emphasizing the importance of personalized dosing. This study aimed to develop and apply a repository of currently published population pharmacokinetic (PopPK) models of caffeine in preterm infants to facilitate model-informed precision dosing (MIPD).Research design and methods: Literature search was conducted using PubMed, Embase, Scopus, and Web of Science databases. Relevant publications were screened, and their quality was assessed. PopPK models were reestablished to develop the model repository. Covariate effects were evaluated and the concentration-time profiles were simulated. An online simulation and calculation tool was developed as an instance.Results: Twelve PopPK models were finally included in the repository. Preterm infants' age and body size, especially the postnatal age and current weight, were identified as the most clinically critical covariates. Simulated blood concentration-time profiles across these models were comparable. Caffeine citrate-dose regimen should be adjusted according to the age and body size of preterm infants. The developed online tool can be used to facilitate clinical decision-making.Conclusions: The first developed repository of PopPK models for caffeine in preterm infants has a wide range of potential applications in the MIPD of caffeine.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"923-938"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142019912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiometabolic complications in children and adolescents with HIV on antiretroviral therapy. 接受抗逆转录病毒疗法的艾滋病儿童和青少年的心脏代谢并发症。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-09-01 Epub Date: 2024-08-30 DOI: 10.1080/17425255.2024.2395562

Camilla Muccini, Martina Bottanelli, Antonella Castagna, Vincenzo Spagnuolo

{"title":"Cardiometabolic complications in children and adolescents with HIV on antiretroviral therapy.","authors":"Camilla Muccini, Martina Bottanelli, Antonella Castagna, Vincenzo Spagnuolo","doi":"10.1080/17425255.2024.2395562","DOIUrl":"10.1080/17425255.2024.2395562","url":null,"abstract":"Introduction: The course of HIV infection has changed radically with the introduction of antiretroviral therapy (ART), which has significantly reduced mortality and improved quality of life. However, antiretroviral drugs can cause adverse effects, including cardiometabolic complications and diseases, which are among the most common. Compared to the adult population, there are fewer studies in the pediatric population on treatment-related complications. The purpose of this review is to provide an update on the literature regarding cardiometabolic complications and diseases in children and adolescents with HIV.Areas covered: A comprehensive literature review was conducted using PubMed and related bibliographies to provide an overview of the current knowledge of metabolic complications (dyslipidemia, insulin resistance, lipodystrophy, weight gain and liver complications) and diseases (prediabetes/diabetes and cardiovascular diseases) associated with ART in children and adolescents with HIV.Expert opinion: Metabolic complications are conditions that need to be closely monitored in children and adolescents with HIV, as they increase the risk of early development of non-communicable diseases, such as cardiovascular disease. Key areas for improvement include ensuring access to treatment, reducing side effects and improving diagnostic capabilities. Overcoming existing challenges will require collaborative efforts across disciplines, advances in technology, and targeted interventions to address socioeconomic disparities.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"893-905"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142116451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Milvexian, a novel factor XIa inhibitor for stroke prevention: pharmacokinetic and pharmacodynamic evaluation. 用于预防中风的新型 XIa 因子抑制剂 Milvexian：药代动力学和药效学评估。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-09-01 Epub Date: 2024-09-02 DOI: 10.1080/17425255.2024.2399721

Alessandro Marè, Arianna Cella, Yan Tereshko, Francesco Toraldo, Gian Luigi Gigli, Mariarosaria Valente, Giovanni Merlino

{"title":"Milvexian, a novel factor XIa inhibitor for stroke prevention: pharmacokinetic and pharmacodynamic evaluation.","authors":"Alessandro Marè, Arianna Cella, Yan Tereshko, Francesco Toraldo, Gian Luigi Gigli, Mariarosaria Valente, Giovanni Merlino","doi":"10.1080/17425255.2024.2399721","DOIUrl":"10.1080/17425255.2024.2399721","url":null,"abstract":"Introduction: Antiplatelets and oral anticoagulants are commonly used to treat patients with various cardiovascular and cerebrovascular diseases. However, the primary concern for clinicians remains the risk of bleeding, thus necessitating the development of new therapies. Milvexian is a new anticoagulant that inhibits factor XIa, preventing the pathological formation of thrombi without increasing bleeding risk.Areas covered: This drug evaluation examines the pharmacokinetic properties of milvexian and provides information on its pharmacodynamics and clinical efficacy in treating some cerebrovascular conditions.Expert opinion: Milvexian shows a good pharmacokinetic profile with low renal elimination rates, justifying its use in patients with a high degree of renal impairment, and without relevant drug-drug interactions. In patients affected by acute non-cardioembolic ischemic stroke or high-risk transient ischemic stroke, milvexian, in addition to dual antiplatelet therapy, seems to have a positive efficacy profile without any safety concerns, especially in terms of intracranial hemorrhage. Two phase 3 trials are ongoing to investigate the efficacy and safety of milvexian for preventing cardioembolic and non-cardioembolic ischemic stroke.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"873-880"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142116452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Population toxicokinetics of carbamazepine and its metabolite carbamazepine-10,11-epoxide in adults. 成人体内卡马西平及其代谢物卡马西平-10,11-环氧化物的人群毒物动力学。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-08-01 Epub Date: 2024-07-21 DOI: 10.1080/17425255.2024.2381555

Vladan Lukic, Slobodan M Jankovic, Nemanja Z Petrovic, Slavica Vucinic, Jasmina Jovic Stosic, Snezana Djordjevic, Viktorija Dragojevic-Simić

{"title":"Population toxicokinetics of carbamazepine and its metabolite carbamazepine-10,11-epoxide in adults.","authors":"Vladan Lukic, Slobodan M Jankovic, Nemanja Z Petrovic, Slavica Vucinic, Jasmina Jovic Stosic, Snezana Djordjevic, Viktorija Dragojevic-Simić","doi":"10.1080/17425255.2024.2381555","DOIUrl":"10.1080/17425255.2024.2381555","url":null,"abstract":"Background: Carbamazepine is one of the most commonly used antiseizure medications. Although carbamazepine pharmacokinetics in epileptic patients is well described, much less is known about these processes in the patients who experienced self-poisoning episode by this drug. Therefore, the aim of our investigation was to perform population toxicokinetics of carbamazepine and its metabolite carbamazepine-10,11-epoxide in adults.Research design and methods: Software program NONMEM and the ADVAN2 TRANS2 subroutine were used for establishing a population toxicokinetic model for the estimation of clearance and volume of distribution based on of the sum values of carbamazepine and carbamazepine-10,11-epoxide concentrations.Results: Our results indicated that the adult patients' ability to eliminate carbamazepine and carbamazepine-10,11-epoxide following acute carbamazepine self-poisoning was strongly associated with the high levels of CRP and ASP, as well as by the treatment with sedation.Conclusions: Our study should provide better understanding of the toxicokinetics of carbamazepine taken in overdose and better management of patient population admitted to hospital.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"817-825"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141636241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Population pharmacokinetics of olanzapine in pediatric patients with psychiatric disorders. 奥氮平在儿科精神病患者中的群体药代动力学。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-08-01 Epub Date: 2024-07-23 DOI: 10.1080/17425255.2024.2380472

Yan-Nan Zang, Zhou Wan, Fei Jia, Qi Yang, Chen-Geng Liu, Qian Wang, Shan-Shan Liu, Fang Dong, An-Ning Li, Jose de Leon, Gang Wang, Can-Jun Ruan

{"title":"Population pharmacokinetics of olanzapine in pediatric patients with psychiatric disorders.","authors":"Yan-Nan Zang, Zhou Wan, Fei Jia, Qi Yang, Chen-Geng Liu, Qian Wang, Shan-Shan Liu, Fang Dong, An-Ning Li, Jose de Leon, Gang Wang, Can-Jun Ruan","doi":"10.1080/17425255.2024.2380472","DOIUrl":"10.1080/17425255.2024.2380472","url":null,"abstract":"Objective: To develop and validate a population pharmacokinetic (PPK) model of oral olanzapine in pediatric Chinese patients in order to individualize therapy in this population.Methods: A total of 897 serum concentrations from 269 pediatric patients taking oral olanzapine (ages 8-17 years) were collected. Demographic parameters, biological characteristics and concomitant medications were investigated as covariates. The data were analyzed using a nonlinear mixed-effects modeling approach. Bootstrapping (1000 runs), normalized prediction distribution error (NPDE), and external validation of 62 patients were employed. Simulations were performed to explore the individualized dosing regimens in various situations.Results: The one-compartment model with first-order absorption and elimination had an apparent clearance (CL/F) of 10.38 L/h, a distribution volume (V/F) of 9.41 L/kg and an absorption rate constant (Ka) fixed at 0.3 h-1. The equation was CL∕F (L∕h) = 10.38 × (body weight∕60)0.25 ×1.33 (if male) × 0.71 (if co-occurrence of infection) × 0.51 (if co-therapy with fluvoxamine) × 1.27 (if co-therapy with sertraline) × 1.43 (if co-therapy with valproate). The final model had satisfactory stability, robustness, and predictive ability. The results from a simulation suggested the oral olanzapine doses required for male and female pediatric patients weighing between 40 and 60 kg without co-medication were 10-15 mg/day and 7.5-10 mg/day, respectively, and dosage adjustments should be based on sex and body weight; and co-administrated with valproate, sertraline, or fluvoxamine.Conclusion: This model may help individualize optimum dosing of oral olanzapine for pediatric patients.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"827-840"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141621968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacokinetic evaluation of ibrexafungerp for the treatment of vulvovaginal candidiasis and beyond. 用于治疗外阴阴道念珠菌病及其他疾病的伊曲沙芬格普药代动力学评估。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-08-01 Epub Date: 2024-07-03 DOI: 10.1080/17425255.2024.2373095

Gage M Dixon, James S Lewis, George R Thompson

{"title":"Pharmacokinetic evaluation of ibrexafungerp for the treatment of vulvovaginal candidiasis and beyond.","authors":"Gage M Dixon, James S Lewis, George R Thompson","doi":"10.1080/17425255.2024.2373095","DOIUrl":"10.1080/17425255.2024.2373095","url":null,"abstract":"Introduction: Ibrexafungerp is a new triterpenoid antifungal agent with activity against a variety of fungal species, including Aspergillus spp. and echinocandin-resistant Candida spp.Areas covered: This evaluation will summarize currently available clinical evidence on the use of ibrexafungerp in the treatment/prevention of vulvovaginal candidiasis (VVC) and detail the mechanism of action, pharmacokinetic/pharmacodynamic parameters, and ongoing/latest research involving ibrexafungerp.Expert opinion: The evidence involving the utilization of ibrexafungerp for the treatment of VVC shows that it is superior when compared to placebo and has comparable clinical cure rates when compared with fluconazole. Ibrexafungerp demonstrates reliable coverage against several Candida spp. including echinocandin-resistant strains, Candida auris, and Aspergillus spp. For VVC, a dose of 300 mg (two 150 mg tablets) twice daily is recommended and does not require dose adjustments based on renal or hepatic function. The use of ibrexafungerp outside of VVC is currently under study with several ongoing trials showing promising interim data.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"713-718"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141494583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacokinetic review of janus kinase inhibitors and its clinical implications for the management of rheumatoid arthritis. anus 激酶抑制剂的药代动力学回顾及其对类风湿关节炎治疗的临床意义。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-08-01 Epub Date: 2024-06-26 DOI: 10.1080/17425255.2024.2373092

S Chandrashekara

{"title":"Pharmacokinetic review of janus kinase inhibitors and its clinical implications for the management of rheumatoid arthritis.","authors":"S Chandrashekara","doi":"10.1080/17425255.2024.2373092","DOIUrl":"10.1080/17425255.2024.2373092","url":null,"abstract":"Introduction: In the realm of autoimmune rheumatic diseases, understanding JAK inhibitors (JAKi) nuances is vital. Baricitinib, tofacitinib, upaacitinib, filgotinib, and peficitinib exhibit subtle yet impactful pharmacokinetic (PK) and pharmacodynamic (PD) variations.Areas covered: This narrative review critically assesses PK and PD distinctions among globally approved JAKi for rheumatoid arthritis, which primarily guide clinical decisions in autoimmune diseases, particularly rheumatoid arthritis. It explores the intricate JAK-STAT signaling pathway, offering insights into JAKs' roles in inflammation, hematopoiesis, and immune homeostasis. Emphasis on PK parameters, including absorption, distribution, metabolism, and excretion, along with CYP3A4 drug interactions, is highlighted. The review underscores integrating PK and PD properties, considering patient-specific factors like hepatic and renal clearance, for judicious JAKi selection in RA and related autoimmune conditions. The literature has been collected from all available databases based on the review question.Expert opinion: Integrating PK and PD properties with patient-specific factors is pivotal for judicious JAKi selection. Recognizing disparities in PK and PD across diseases, ethnicities, and environmental factors is crucial for personalized JAKi choices. This expert opinion underscores the significance of a second compartment analysis, elucidating the interplay between PK and PD and its impact on JAKi efficacy.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"741-748"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141447871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dose optimization of β-lactam antibiotics in children: from population pharmacokinetics to individualized therapy. 儿童使用β-内酰胺类抗生素的剂量优化：从群体药代动力学到个体化治疗。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-08-01 DOI: 10.1080/17425255.2024.2385403

Perrin Ngougni Pokem, Dorian Vanneste, Stef Schouwenburg, Alan Abdulla, Matthias Gijsen, Evelyn Dhont, Dimitri Van der Linden, Isabel Spriet, Pieter De Cock, Birgit Koch, Françoise Van Bambeke, Gert-Jan Wijnant

{"title":"Dose optimization of β-lactam antibiotics in children: from population pharmacokinetics to individualized therapy.","authors":"Perrin Ngougni Pokem, Dorian Vanneste, Stef Schouwenburg, Alan Abdulla, Matthias Gijsen, Evelyn Dhont, Dimitri Van der Linden, Isabel Spriet, Pieter De Cock, Birgit Koch, Françoise Van Bambeke, Gert-Jan Wijnant","doi":"10.1080/17425255.2024.2385403","DOIUrl":"10.1080/17425255.2024.2385403","url":null,"abstract":"Introduction: β-Lactams are the most widely used antibiotics in children. Their optimal dosing is essential to maximize their efficacy, while minimizing the risk for toxicity and the further emergence of antimicrobial resistance. However, most β-lactams were developed and licensed long before regulatory changes mandated pharmacokinetic studies in children. As a result, pediatric dosing practices are poorly harmonized and off-label use remains common today.Areas covered: β-Lactam pharmacokinetics and dose optimization strategies in pediatrics, including fixed dose regimens, therapeutic drug monitoring, and model-informed precision dosing are reviewed.Expert opinion/commentary: Standard pediatric doses can result in subtherapeutic exposure and non-target attainment for specific patient subpopulations (neonates, critically ill children, e.g.). Such patients could benefit greatly from more individualized approaches to dose optimization, beyond a relatively simple dose adaptation based on weight, age, or renal function. In this context, Therapeutic Drug Monitoring (TDM) and Model-Informed Precision Dosing (MIPD) emerge as particularly promising avenues. Obstacles to their implementation include the lack of strong evidence of clinical benefit due to the paucity of randomized clinical trials, of standardized assays for monitoring concentrations, or of adequate markers for renal function. The development of precision medicine tools is urgently needed to individualize therapy in vulnerable pediatric subpopulations.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"787-804"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141794286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How can we better address the pharmacokinetics of antipsychotics in children and adolescents? 如何更好地处理儿童和青少年抗精神病药物的药代动力学问题？

Expert opinion on drug metabolism & toxicology Pub Date : 2024-08-01 Epub Date: 2024-07-12 DOI: 10.1080/17425255.2024.2378887

Georgios Schoretsanitis, Jose de Leon, Christoph U Correll

{"title":"How can we better address the pharmacokinetics of antipsychotics in children and adolescents?","authors":"Georgios Schoretsanitis, Jose de Leon, Christoph U Correll","doi":"10.1080/17425255.2024.2378887","DOIUrl":"10.1080/17425255.2024.2378887","url":null,"abstract":"Introduction: Despite a steady increase of antipsychotic prescriptions in children and adolescents, knowledge about pharmacokinetics and dosing of antipsychotics in children and adolescents remains limited.Areas covered: We discuss seven issues with major impact on the pharmacokinetics of antipsychotics in youth: estrogens, ii) obesity, iii) ethnicity, iv) smoking, v) inflammation, vi) drug-drug interactions (DDIs), and vii) pharmacogenetics. Despite their major impact, these issues have not been adequately considered in the context of dosing algorithms for antipsychotics in youth. A simple tool to quantify the impact of these pharmacokinetics issues on antipsychotics is therapeutic drug monitoring (TDM), which refers to the quantification of the prescribed medication in the blood of the patients, as a surrogate for the peripheral antipsychotic exposure. We also provide summary tables extrapolated from the adult literature on metabolism, therapeutic reference ranges (TRRs) and DDIs.Expert opinion: Despite considerable experience with TDM for antipsychotics in the management of other patient subgroups, TDM use for antipsychotics in children and adolescents may be limited with TRRs invariably being extrapolated from adult patients. Advancing TDM knowledge is expected to help clinicians address the special properties of pharmacokinetics of antipsychotics and ultimately enable antipsychotic dose individualization in youth.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"719-726"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141565406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent progress in adverse events of carboxylic acid non-steroidal anti-inflammatory drugs (CBA-NSAIDs) and their association with the metabolism: the consequences on mitochondrial dysfunction and oxidative stress, and prevention with natural plant extracts. 羧酸类非甾体抗炎药（CBA-NSAIDs）不良反应及其与新陈代谢关系的最新进展：对线粒体功能障碍和氧化应激的影响，以及天然植物提取物的预防作用。

Expert opinion on drug metabolism & toxicology Pub Date : 2024-08-01 Epub Date: 2024-07-12 DOI: 10.1080/17425255.2024.2378885

Yanan Liu, Chao Yang, Jieying Zhang, Awais Ihsan, Irma Ares, Marta Martínez, Bernardo Lopez-Torres, María-Rosa Martínez-Larrañaga, Xu Wang, Arturo Anadón, María-Aránzazu Martínez

{"title":"Recent progress in adverse events of carboxylic acid non-steroidal anti-inflammatory drugs (CBA-NSAIDs) and their association with the metabolism: the consequences on mitochondrial dysfunction and oxidative stress, and prevention with natural plant extracts.","authors":"Yanan Liu, Chao Yang, Jieying Zhang, Awais Ihsan, Irma Ares, Marta Martínez, Bernardo Lopez-Torres, María-Rosa Martínez-Larrañaga, Xu Wang, Arturo Anadón, María-Aránzazu Martínez","doi":"10.1080/17425255.2024.2378885","DOIUrl":"10.1080/17425255.2024.2378885","url":null,"abstract":"Introduction: Carboxylic acid non-steroidal anti-inflammatory drugs (CBA-NSAIDs) are extensively used worldwide due to their antipyretic, analgesic, and anti-inflammatory effects. CBA-NSAIDs have reasonable margin of safety at therapeutic doses, and in the current climate, do not possess addiction potential like opioid drugs. Studies have revealed that various adverse events of CBA-NSAIDs are related mitochondrial dysfunction and oxidative stress.Areas covered: This review article summarizes adverse events induced by CBA-NSAIDs, mechanisms of mitochondrial damage, oxidative stress, and metabolic interactions. Meanwhile, this review discusses the treatment and prevention of CBA-NSAIDs damage by natural plant extracts based on antioxidant effects.Expert opinion: CBA-NSAIDs can induce reactive oxygen species (ROS) production, mediate DNA, protein and lipid damage, lead to imbalance of cell antioxidant status, change of mitochondrial membrane potential, activate oxidative stress signal pathway, thus leading to oxidative stress and cell damage. Adverse events caused by CBA-NSAIDs often exhibit dose and time dependence. In order to avoid adverse events caused by CBA-NSAIDs, it is necessary to provide detailed patient consultation and eliminate influencing factors. Moreover, constructive research studies on the organ-specific toxicity and mechanism of natural plant extracts in preventing and treating metabolic abnormalities of CBA-NSAIDs, will provide important value for warning and guidance for use of CBA-NSAIDs.","PeriodicalId":94005,"journal":{"name":"Expert opinion on drug metabolism & toxicology","volume":" ","pages":"765-785"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141565407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0